On November 3, 2017 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, 2017, at The Phoenician in Scottsdale, Arizona (Press release, Karyopharm, NOV 3, 2017, View Source [SID1234521544]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 3, 2017 Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reported that Steven Klosk, President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on November 8, 2017 at 10:00 a.m. EST in New York City (Press release, Cambrex, NOV 3, 2017, https://www.cambrex.com/cambrex-present-stephens-fall-investment-conference/ [SID1234521556]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Know more, wherever you are:
Latest on Cambrex Corporation’s Cancer Pipeline, book your free 1stOncology demo here.

The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under "Webcasts & Presentations", and a replay will be available for 90 days after the live event concludes.

Cerus has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Cerus, 2017, NOV 3, 2017, View Source [SID1234521550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 3, 2017 Portola Pharmaceuticals (Nasdaq:PTLA) reported that Bill Lis, chief executive officer, will present at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, at 8:40 a.m. Mountain Time in Scottsdale, AZ (Press release, Portola Pharmaceuticals, NOV 3, 2017, View Source [SID1234521546]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and available for replay for 30 days following the presentation on the Credit Suisse website.

On November 3, 2017 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported that new data will be presented in an oral presentation and a trial in progress poster at the upcoming CTOS meeting that will be held November 8-11 at the Grand Wailea Resort in Hawaii (Press release, Adaptimmune, NOV 3, 2017, View Source [SID1234521554]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sandra P. D’Angelo of Memorial Sloan Kettering Cancer Center will be presenting an update on the company’s ongoing study of NY-ESO SPEAR T-cells in synovial Sarcoma. There will also be a trial in progress poster for the ongoing study of NY-ESO SPEAR T-cells in Myxoid/Round Cell Liposarcoma (MRCLS). Details are below:

Oral Presentation:

Title: Open Label Non-Randomized Multi-Cohort Pilot Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells in HLA-A2+ Patients with Synovial Sarcoma (NCT01343043)
– Abstract ID: 2804696
– Session Title: Symposium 1: Medical, Pediatric and Young Adult Oncology
– Session Time: November 9, 2017 from 10:30 AM to 12:00 PM
– Location: Haleakala 1
Trial in Progress Poster:

Title: A Pilot Study of NY-ESO-1 SPEAR T-Cells in Subjects with Advanced Myxoid/Round Cell Liposarcoma (NCT02992743)
– Abstract ID: 2804696
– Presentation time: The poster will be on display throughout the meeting.
– Poster Session: November 9, 2017 from 5:30 PM to 6:30 PM
– Location: Haleakala 2 & 3